Dean&Francis
ISSN 2959-409X

Advanced Delivery Systems for Telomere-Targeting Nucleic Acid Therapeutics

Xuan Chen

Faculty of Mathematical and Physical Sciences, University College London, London, UK
Corresponding author: shane.chen.22@ucl.ac.uk

Abstract:

Nucleic acid therapeutics can provide precise sequence programmability for cancer and aging-related telomeres and telomerase, but their clinical translation is still severely limited due to rapid nuclease degradation, endosomal trapping and mainly the nuclear barrier. This paper systematically reviews the landscape of delivery methods designed to overcome these physiological barriers and seeks to bridge the gap from molecular design in the laboratory to actual in vivo proof of concept in animal models. Foundational chemical changes like Phosphorothioate backbones and Locked Nucleic Acids are seen as crucial for enhancing stability and binding affinity. In addition to this, viral vectors, LNPs (Lipid Nanoparticles), polymeric systems, etc., different kinds of carrier platforms are also analyzed for observing the overall performance of this system to obtain balanced results with regard to efficiency of nuclear transduction, safety, and manufacturing scale. This paper emphasizes focusing on synergy, using "stealth" carriers for systemic circulation with specific nuclear localization signals (NLS) so that the payload is deposited at the chromosomal ends. This paper aims to summarize current progress on the adaptation relationships between delivery routes and telomere-specific demands and to offer a reference on how to choose an appropriate delivery strategy for oncology and regenerative medicine.

Keywords: Telomere targeting; Nucleic acid therapeutics; Drug delivery systems; Chemical modification; Nanocarriers.

1. Introduction

With the rapid development of biomedical technology, nucleic acid therapeutic agents are beginning to be regarded as the third major category of therapeutic agents, other than small molecule drugs and antibodies [1]. Nucleic acid drugs are underpinned by the Watson-Crick base pairing rule, and this gives them one significant advantage on the molecular design side of things: it allows for sequence programmabil-

ISSN 2959-409X

ity. Targets like telomeres and telomerase are very particular in the sequences, be it the iconic TTAGGG repeat or the template sequence of hTR.

However, it faces a substantial physical barrier going from sequences in the lab into something that can be used in the clinic. Deep down in the cell, its telomeres sit at the very tips of every single piece of DNA-it is like demanding an entire new field of specialized delivery strategies [2, 3]. Therapeutic molecules need to get past both the hydrophobic barrier of the cell membrane plus the cytosolic nuclease degradation, yet can make their way through the NPC and reach chromosomal ends accurately [1, 4]. Thus, this requirement for high spatial specificity created a significant chasm between what is seemingly simple molecular design and the complexity of in vivo delivery.

In this case, building efficient telomere-targeting delivery systems has high significance both in research and practice. First, in terms of clinical application, making advances on delivery bottlenecks is to tap the full potential of nucleic acid medicines and use them widely for anti-tumor and anti-aging treatments. With the assistance of the delivery system and therapeutic payload being utilized together, the theoretical gene regulation turns into a real effect in the clinic. Secondly, speaking of drug development, once we solve the drug delivery of telomeres, which is an 'elusive' intranuclear target, then how we proceed would have an even wider strategic and technical reference for all other intranuclear target drugs [2]. Lastly, it is the progress of the field that is being driven by the development of delivery vectors with high biosafety, along with high transport efficiency. This is a critical milestone—the beginning of nucleic acid therapies moving from just being used for very rare diseases to being used for all kinds of common and ongoing illnesses as well [1].

This paper focuses on the delivery problems of telomere-targeted nucleic acid therapy in vivo, and comprehensively collects the research achievements in the fields of chemical modification, nanocarriers and synergistic strategies, summarizes the main evaluation indexes of the delivery system, and intends to clarify the particular adaptation relationship between each technical path and the needs of telomere targeting to give targeted references for further studies in this field.

2. Core Challenges of in Vivo Delivery of Telomere-Targeting Nucleic Acid Therapeutics

2.1 Common Challenges Arising from Basic Physicochemical Properties

2.1.1 Negative charge & hydrophilicity

Nucleic acid drugs are large, highly polar anions that do not readily cross cell membranes. Due to their strong negative charge and hydrophilicity, they can never achieve an effective passive diffusion through the hydrophobic lipid bilayer [1]. This is also a shared bottleneck for all nucleic acid drugs, which holds for telomere-targeted medications as well. And it is not just a challenge of this kind, but for the effectiveness of this kind of drug, it has become a core prerequisite. Because most telomere-related targets (such as telomerase) are located in the cell or even in the cell nucleus, without cellular uptake, the following binding of telomeres and action cannot be completed. Researchers admit this to be factual: delivery systems must propagate those negatively charged nucleic acids past bodily membranes in order that cellular uptake be successful. For example, telomere-mimicking T-oligo DNA (an 11-mer oligonucleotide) all by itself has difficulty getting inside cells; once it complexes with a cationic peptide, though, it sees a significant increase in uptake—about 15 times as much—due to the charge neutralization [5]. This is no small feat just for telomere-targeted medicines, but they must be overcome for the medicines to have an effect.

2.1.2 Nuclease degradation & short half-life

Naked nucleic acid in biofluid is unstable and is degraded by serum intracellular nucleases in a short time [1, 5]. If not protected, then it will have a very short half-life in circulation. It is also noted in some studies, telomere 3′-overhang mimic ("T-oligo") is limited in stability due to serum nucleases.

2.1.3 Immunogenicity

Exogenous nucleic acids can elicit innate immune reactions as they are recognized by pattern-recognition receptors, viz., Toll-like receptors and RIG-I-like receptors. The inflammation can be caused as well by the activation of the immune system, the fast removal of the therapy, or the systemic toxicity via interferon signaling. Telomere-related, in applications that need repeated administration or long-term therapy, the immunogenicity will bring more danger because chronic inflammation already exists in aged tissues. After immune activation, it might worsen the chronic inflammation and affect stable telomere function regulation [2].

2.2 Key Obstacles in Intracellular Transport

2.2.1 Endosomal sequestration

Most nucleic acid-destined drugs, after cellular absorption, end up entrapped. After being taken up, most nucleic acids internalized by endocytic processes are enclosed in endosomes. A lot of these then get carried off to the lysosomes for digestion before they ever reach the actual intracellular locations that have any effect. This endosomal trapping is very damaging to telomere drugs, because their targets are in the nucleus. If the drug can get inside

the cell but is unable to escape the endosome, then there is no way it will be able to get near the nuclear envelope or traverse the NPC to bind to telomeres. Severely limiting the amount of intracellularly available bioavailability, and it is an important rate-limiting step in being effective [1].

2.2.2 Nuclear access limitation

Telomere biology is connected to nuclear processes; telomerase function and telomeric DNA preservation all take place inside the nucleus. Nucleic acid treatments seeking to shut down telomerase, or make contact with telomeric DNA, need to get through the nuclear envelope. Unlike cytosolic targets, telomere-targeted drugs also face another barrier: the nuclear pore complex [3].

2.3 Telomere-Specific Delivery Obstacles

2.3.1 Telomere structural accessibility

Telomeres are sheltered by the shelterin complex and the higher-order DNA construction that physically hides the chromosome end. It creates different steric and thermodynamic barriers for telomere-targeted nucleic acids—exogenous oligos have to base pair against telomeric DNA or bind the extracellular telomerase-associated RNA, but to do it, they must first break through physical obstructions imposed by shelterin. They also have to overcome the spatial blockages due to G-quadruplex formation (which is not a problem for mRNA-based cytosolic RNA acting therapeutics). Such structural shielding is a specific barrier for this kind of telomere-targeting method and does not occur when delivering into cells via cytosolic RNA targets [3].

2.3.2 Off-target distributions, bio-distribution

Systemically administered nucleic acid drugs have a distribution which seems to be notoriously nonspecific; it leans toward organs like the liver, spleen and the bone marrow. This kind of biodistribution pattern not only limits the amount of drug that shows up where you want it most, but it also raises the odds for an unintended biological outcome. In cancer treatment, there is worry about hurting other, normal, multiplying parts of the body, and with aging applications too, tweaking telomerase that isn't cancerous could make cancer risk increase [2].

3. Nucleic Acid Chemical Modification Strategies

Before complicated nanocarrier systems came along, chemical modification was the foundational strategy for making nucleic acid therapies more "druggable. After a decade of research, almost all successful clinical interventions use fine-tuned chemical engineering of the oligonucleotide backbone, the ribose sugar rings or the nucleobases in order to make up for the intrinsic instability themselves [2].

3.1 Backbone Modification

The most popular form of structural change is substituting a non-bridging oxygen atom within the phosphodiester connection for a sulfur atom to produce a phosphorothioate (PS) backbone. There is some change in the chirality, and the nuclease resistance has increased as well. It improves the ability of oligonucleotides to bind to serum proteins, with a PS backbone, especially for serum albumin, to lower the renal clearance and also prolong the circulation half-life in vivo. However, this method also has certain shortcomings: if PS is over-modified, there will be nonspecific protein binding, it may cause cytotoxicity, abnormality of blood coagulation and so on, and it may slightly affect the binding affinity to the target RNA sequence [2].

3.2 Sugar Ring Modification

The 2'-hydroxyl (-OH) group of the ribose ring is the most chemically active site, and it is also the main site of endonucleolytic attack. Modifications like 2'-O-Methyl (2'-OMe) and 2'-Fluoro (2'-F) not only reduce the activity of nucleases, but also cause the RNA to adopt a C3'-endo conformation (A-form helix). Correction of this conformational bias leads to high Tm and binding affinity. These 2' modifications allow for "immunosilencing, in which there will be no detection from the TLRs of the exogenous siRNAs, so problems with the immune system shouldn't occur. These sugar ring modifications are good at targeting the short tandem repeat of telomeres (TTAGGG) because their strong, rigid structure resists the hybridization resistance that comes from the way telomeric DNA is structured, and they can bind really well to telomere sequences or hTR. LNA makes a methylene bridge between 2'-O and 4'-C, locking the ribose in a rigid conformation. LNA-modified ASOs have excellent heat stability, so they're really good for binding to short telomere sequences—such as miRNAs or repetitive DNA motifs [1].

3.3 Conjugation Strategies

Beyond structure changes, ligand conjugation has become quite a game-changer. The covalent connection between N-acetylgalactosamine (GalNAc) and the 3'-end of siRNAs or ASOs is a landmark in this field. This triantennary ligand binds exactly to the Asialoglycoprotein Receptor (ASGPR - on hepatocytes) via the Receptor-mediated Endocytosis process, taking place very efficiently. For telomere-targeting therapy, it has immediate significance in HCC in which telomerase is anomalous: Upon the GalNAc-mediated hepatocyte-precise delivery, the drug will accumulate precisely at the lesion area, where it will maintain normal function of telomere in normal hepatic cells [6]. Alternatively, oligonucleotide conjugation—such

ISSN 2959-409X

as adding cholesterol, palmitic acid, or tocopherol (Vitamin E)—makes oligos able to get inside cells through the lipoprotein pathway (hijacking of circulating lipoproteins such as LDL and HDL) and at the same time becomes more hydrophobic, which is more likely to interact with the membrane. This is good for telomere drugs because they have to get across the cell membrane first before getting to the cytoplasm, so if it makes it easier for these drugs to cross the membrane, this step makes it much more likely for them to enter the cell nucleus [4].

4. Delivery Vector Systems for Telomere-Targeting Nucleic Acid Drugs

4.1 Lipid Nanoparticles (LNPs)

Lipid nanoparticles (LNPs) are already the top non-viral delivery system for telomere-targeted nucleic acid therapies, and this pivot from experimental proof-of-concept to full clinical dominance came thanks largely to the success of COVID-19 mRNA vaccines. The efficacy or success of this platform is based on the exact microfluidic construction of four essential lipid portion components into quite a complicated microstructural item, instead of a simple liposome; ionizable cationic lipids, helper lipids, cholesterol and PEGylated lipids. Among them the ionizable lipid (such as DLin-MC3-DMA, SM-102) as the functional nucleus, with a certain pKa (generally 6.5 or lower) to remain electrically neutral and avoid toxicity and immune clearance under physiological pH but protonate under low pH inside the endosome to cause membrane destabilization in the form of hexagonal phase and promote its release into the cytosol [7, 8]. Structural integrity and fluidity are controlled by helper lipids like distearoylphosphatidylcholine (DSPC) and cholesterol that fill packing defects and prevent leakage, and surface-anchored PEG lipids provide a hydration layer to retard opsonization and extend circulation half-life, though their eventual shedding is needed to permit cellular uptake.

For telomere targeting, the ability of LNPs to carry payload into the cytoplasm is quite important too; Firstly, this would make it possible for siRNAs targeting hTERT to suppress its mRNA expression, and it would provide for enrichment of nucleic acid drugs at the nucleus. In addition, the introduction of the SORT Lipids also has a Selective Organ Targeting (SORT) function, which can precisely target the tumor tissue, and there is no obvious non-specific effect on telomeres in other normal tissues [9]. From the perspective of telomerase inhibition, this kind of sophisticated system has allowed effective systemic release of siRNAs with targeting capability for hTERT, like the case with LNPs formed using DLin-MC3-DMA that showed its power in crossing over the complicated bone marrow obstruction within chronic myeloid leukemia cases where it can achieve around 100 percent absorption within the hematopoietic part and lowering of leukemia load mainly through the silencing effects on BCR-ABL and telomerase. There have been some advances about it in this area in more recent times that have extended this to combinatorial 'restore and inhibit' strategies for advanced prostate cancer, in which LNPs have begun co-delivering PTEN mRNA alongside hTERT/AR siRNAs, producing more potent and synergistic anti-tumor effects, establishing the efficacy of the platform as a multi-modal genetic modulator.

4.2 Polymeric Nanocarriers

Polymeric nanocarriers, especially those made up of poly(lactic-co-glycolic acid) (PLGA) and then modified by adding cationic polymers, such as chitosan, use very specific ways to solve two big problems: getting medicine inside cells on a constant basis and escaping from endosomes. The main point about the usefulness of PLGA is that it has a degradation process, and this is controlled by the splitting of its backbone through hydrolysis. This is not an inactive process, but instead autocatalytic, since the cleavage of ester bonds results in carboxylic acid termini, which locally protonate the matrix and lower its pH, which then causes further hydrolytic degradation, resulting in a “bulk erosion” profile that would allow sustained release of anti-hTERT treatment for days to weeks. To tackle the problem of endosomal sequestration—anionic PLGA would be sequestered and degraded—engineers have formed core–shell structures by depositing PLGA onto chitosan. The effect of this design depends on the “proton sponge” effect; the high density of primary amine groups (pKa ~ 6.5) on the chitosan shell has a very high ability to buffer the acidic environment (pH 5.0-6.0) of the endosome. The amines, because they’re getting protonated, sequester protons pumped by V-ATPase, and what’s going to happen is an inflow of chloride and water to offset the charge and osmotic imbalance, and that’s going to result in an osmotic swelling, a physical rupture of the endosome and then release of the siRNA payload into the cytosol [10]. In order to achieve tumor-specific uptake, there has been experimentation altering ligands chemically using coupling like carbodiimide, to covalently attach folic acid to the polymer. For example, Folate-modified PLGA nanoparticles were made to carry both hTERT siRNA and the PI3K inhibitor Wortmannin [11]. This setup took advantage of the abundance of folate receptors on cancer cells to help the drugs get inside by receptor-mediated endocytosis; by stopping both the hTERT gene and the upstream PI3K/Akt phosphorylation loop that makes telomerase work, it produced a powerful "two-in-one" effect that was much better than using single therapies.

4.3 Viral Vectors

Viral vectors get on fine by manipulating evolutionarily effective transfer mechanisms; nevertheless, completion of tropism restructuring together with replication logic modification must be achieved via means of both chemical conjugations and genetic alteration so as to put these entities into practice with respect to cancer operation. In order to get away from the bottleneck of Ad5, which can naturally accumulate in the liver because of the binding to Coxsackie Adenovirus Receptor (CAR), researchers implemented a "chemical retargeting" strategy known herein as Mannan-Ad. This architecture is produced by oxidizing mannan polysaccharides to create reactive aldehyde groups, which form stable Schiff bases with the amine groups of lysine residues on the viral capsid protein, leading to a steric mask on native CAR binding sites and an introduction of a high-affinity ligand for the CD206 mannose receptor, highly expressed on DCs. And, this Schiff base remodeling can allow this virus to go around the liver and specifically infect APCs and cause a robust CTL response against the TERT and VEGFR-2 antigens [12, 13]. At the same time, CRAds uses a sort of genetic "logic gate," so it is only replicated in tumorous tissue. Replacing the native viral E1A promoter with the hTERT promoter means that the virus will have to replicate dependent on the cancer-specific transcription factor environment. Especially after the binding of c-Myc/Sp1 complexes is done, it will result in activation within tumor cells. It is different from the repressive Mad1/Max binding and chromatin reorganizing happening in normal somatic cells. Then it can also ensure that a virus and any therapeutic payload (like shRNA) is amplified only within a tumor microenvironment. This is exactly what we target: the virus and its carried therapeutic payload only amplify in telomerase-positive tumor cells, specifically inhibiting telomere-related oncogenic pathways while avoiding damage to normal cells' telomere function, greatly improving safety.

4.4 Inorganic Nanocarriers

Inorganic nanocarriers depend on their structural frameworks being strong, so that complex molecular machines can navigate through the nuclear pore complex (NPC) or act right away when something pushes on them mechanically with an enzyme. Gold Nanoparticles (AuNPs) use a mechanism to cross the hard nuclear membrane barrier and utilize the cell's active transport with the help of the Importin/Ran-GTP pathway. Construction is done by functionalizing the AuNP surface with HIV-1 Tat peptide (Sequence: GRKKRRQRRRPPQ), which is rich in arginine. In terms of what it does on a molecular basis, this cationic peptide mimics an NLS and recruits cytoplasmic importins α and β, and these receptors dock with the NPC and help the nanoparticle enter the nucleoplasm, where a high local concentration of Ran-GTP binds to Importin β, inducing a conformational change that releases the AuNP. Bavelaar et al. used this method for delivering In-labeled antisense oligonucleotides directly into the nucleus so as to cause precise Auger electron-mediated damage to Telomeric DNA [3]. Alternatively, Mesoporous Silica Nanoparticles (MSNs) use a "gatekeeper" method based on DNA conformational dynamics. In this design, the mesopores containing drug (such as doxorubicin) are capped with a DNA oligonucleotide duplex: one strand of this duplex is a telomerase primer sequence. When the cancer cells are exposed to intracellular telomerase, it will add TTAGGG repeats to the primer 3'-end. This elongation forms a rigid G-quadruplex or hairpin, which promotes the formation of a thermodynamically favored structure over the duplex structure and pushes the capping strand off the pore via steric hindrance, and only releases the entrapped drug in telomerase-positive cells. This telomerase-responsive release design achieves a "precision strike" for telomerase-positive cells: the drug is released only in tumor cells that have abnormal telomerase activity and will not disrupt the telomere of normal cells, thereby reducing off-target toxicity.

4.5 Comparison of Vector Systems and Application Scenarios

4.5.1 Carrier performance & endosomal escape

Delivering more total carriers does not—in general—lead to an increase in therapeutic effect; the cell has a bias towards lysosome-mediated degradation of endocytosed material, and getting something into the cytosol is actually an unconventional outcome. So raising the carrier amount mainly intensifies systemic toxicity and immune excitation, but it yields less return in terms of function. So, rather than focusing on maximizing cell uptake, it turns out that improving the per-event efficiency of endosomal escape is the key design objective for a good nucleic acid delivery system: The synthetic vector escape efficiency is generally less than 2% [1]. In this case, Viral vectors get better per particle transfection efficiency, because they use viral fusion proteins and active nuclear localization signals, which are evolutionarily adapted to break through endosomal membranes and hijack cell transporting routes to enter the nucleus [12]. On the contrary, Lipid Nanoparticles (LNPs) are a quite efficient system for cytosol targeted drugs, but they work at a low absolute endosomal escape rate (~2%); they are efficient mainly due to ionizable lipid-induced pH drop, which causes hexagonal phase transition to disrupt membrane, and a high payload to guarantee a sufficient number of therapeutic copies in the cytoplasm [7, 8]. Polymeric nanocarriers can exert the "proton sponge effect," which causes swelling due to osmotic pressure and ruptures the vesicle by buffering

ISSN 2959-409X

capacity, but they don't have very good efficiency because the trade-off between efficiency and cytotoxicity is high [10]. Finally, from a passive escape efficiency perspective, most inorganics show low to moderate escape efficiency as they have weak fusogenic properties that require surface functionalization (like TAT) or externally triggered (Photothermal heating) methods to break out of the endosomal environment, thus would have lower passive escape than well-tuned lipidic systems [3].

4.5.2 Targeting, toxicity and manufacturing

Focusing on specificity, biocompatibility, and manufacturing scale is very important for making nucleic acid medicines work in people; it decides how good the medicine is and if making it will be economically feasible. Viral Vectors have inherent tissue tropism exemplified by AAV9 crossing the BBB but suffer from high immunogenicity risks such as cytokine release syndrome and hepatotoxicity, as well as being severely constrained by pre-existing neutralizing antibodies present in the population and further suffer from production bottlenecks with complex biological fermentations driving costs to > million per dose [12, 14]. On the contrary, Lipid Nanoparticles (LNPs) demonstrate superior biodegradability with a highly tunable targeting profile; while historically limited to hepatocyte delivery by ApoE adsorption, they can now be delivered to the lungs and spleen with SORT lipids easily by simple formulation; this is supported by "best-in-class" microfluidic methods that are robust, scalable and affordable. The polymeric and inorganic nanocarriers mostly use chemical bonding with active ligands like Folate and RGD peptides for specificity, which makes the production more difficult and complex. With respect to the safety of the carrier, polymers such as PLGA are biocompatible and FDA approved, but the cationic polymers like PEI have very high levels of cytotoxicity, and the inorganic nanocarriers have the problem of non-biodegradability and long-term retention in the reticuloendothelial system [10, 15].

5. Comprehensive Strategies to Improve Delivery Efficiency

5.1 Synergistic Action Mechanisms

To effectively transport telomere-targeted nucleic acid therapeutics intracellularly, one has to use a rather complex 'layered defense' approach, where chemical modifications are used in conjunction with nanocarrier engineering. This is done to overcome three successive biological barriers. While lipid nanoparticles (LNPs) or polymeric vectors are used to get past the large-scale transportation barriers—shielding against the serum nucleases, making it across the cell membrane—these still depend on the stability of nucleic acid cargo itself to make it past the rough passage. The synergy for telomere targeting drugs, then, is much more focused: nanocarriers help us with the "translocation problem," and the chemical modification helps us with the "survival and binding problem. Chemical alterations made to the oligonucleotide backbone, mainly by replacing phosphodiester bonds with phosphorothioate (PS) linkages, furnish an initial layer of durability that makes the payload resistant to quick enzymatic decomposition during transient exposure periods associated with encapsulation as well as endosomal pathways [2]. As well as modifications to the ribose sugar such as 2'-O-methyl (2'-OMe) and 2'-fluoro (2'-F) substitutions, which, when combined with the carrier, reduce the immunogenicity of the load, to prevent the activation of nuclear or cytosolic targets of the drug by inflammatory clearance or toxicity before the drug has even reached its target due to activation of Toll-like receptors (TLRs) [1]. At last, the carrier system solves the "entry problem" with the method of proton sponge or membrane fusion, but chemical engineering solves the "survival problem" so that after arrival at the nucleus, the molecule remains intact and retains its bioactivity too [4].

5.2 Optimization Paths for Comprehensive Strategies

The optimization for these complete delivery schemes is arranged following a hierarchy of logic dictated by the location of the target in question, on therapy as well as disease context: For systemic administration, like in metastatic cancer, the main design is circulation stability and evading the RES. This design has both a heavily modified chemical payload (to stand up to serum nucleases) and a "stealth" carrier like PEGylated LNP, which uses active targeting ligands like GalNAc for liver or Folate for tumors to get more targeted accumulation in tissue [1]. For targeting telomeres in metastatic cancer, this should also consider nuclear entry rate – adding nuclear localization signals (such as Tat peptide) to the package surface can increase the amount of nucleic acid drugs accumulated at nuclear telomeres after arriving at the tumor cells.

For local administration, such as intratumoral/inhalation, optimizations revolve around retention and cellular uptake optimization, usually with polymeric PLGA carriers that are bulk erodible and tunable for unmodified/lightly modified T-oligos/ASOs sustained release over weeks without systemic circulation [16]. In local telomere-targeted therapy, it can be released continuously and avoid interference with telomere function for a long time for tumor cells and there is no need to give drugs frequently. It can also reduce the systemic toxicity. In the same way for the nuclear target Telomeric DNA, we need to include the Nuclear Localization Signal (NLS) in our carrier construction; however, if our target is Cytosolic such as hTERT

mRNA, then the key is still to maximize the capacity for the endosomal escape of ionizable lipids or proton-sponge polymers [17].

6. Key Evaluation Metrics and Detection Methods for Delivery Systems

Rigorous characterizations of nucleic acid delivery systems need multiple types of analyses, going further than simple uptake assays. Critical evaluation metrics: Cell internalization efficiency is measured by internal load, but much more important is endosomal escape rate; this is just a small fraction of the overall number of molecules that are released into the cytosol. As for telomere-targeted delivery systems, the essential core index is the nuclear delivery efficacy; unlike cytosolically targeted drugs, it merely evaluates the true effect by the correct calculation of the proportion of medicines entering the cell nucleus and binding with telomeres. Gene silencing/activation efficiency (e.g., hTERT knockdown) is used as the functional readout. From the organism aspect, biodistribution profile and circulation half-life determine off-target hazard and immunogenicity (cytokine release), which assesses safety.

To use advanced detection methods to differentiate trapped cargo from a working drug, we use confocal analysis with colocalization, such as Pearson's coefficient with Lysotracker for endosomal trapping, or more importantly, a novel kind of the Split Luciferase Endosomal Escape Quantification (SLEEQ) assay for a sensitive and numerical readout of cytosolic exposure [17, 18]. In terms of the specific evaluation of binding of telomeres, by using techniques like FISH (Fluorescence in situ hybridization) and also using a drug fluorescence labeling, which can directly visualize the colocalization of the nucleic acid drug with telomeres, this would give a very convincing kind of evidence of the targeted binding. Along with qPCR and WB to do the job of checking the downstream effect as standard, also in vivo bioluminescence imaging takes care of biodistribution tracking in the tissues in real-time [19].

7. Conclusion

Nucleic acid therapeutics, with sequence programmability, represent the ideal tools for targeting telomeres and telomerase (hTR); however, "delivery efficiency" remains the critical bottleneck in translating these from the laboratory to the clinic. Therefore, for telomere targets, a synergistic "layered defense" strategy is essential. Specifically, chemical modifications address the "survival problem" regarding stability and binding affinity, serving as the prerequisite for all therapies. Meanwhile, nanocarriers (e.g., LNPs, polymers, viral vectors) resolve the "entry problem" involving cellular uptake and endosomal escape. Currently, LNPs lead in clinical translation, whereas viral vectors offer superior transduction efficiency. Since there is no "universal" carrier, the system must be adapted according to the administration route. For systemic administration (e.g., in cancer), the focus should be on long-circulation stability and targeting to minimize off-target toxicity in the liver. Conversely, for local administration, sustained-release systems can be employed, prioritizing long-term maintenance and low immunogenicity. Looking forward, R&D efforts should shift from merely increasing "cellular uptake rates" to overcoming rate-limiting steps, specifically improving endosomal escape rates and nuclear entry efficiency. Ultimately, a balance must be struck between high potency, biosafety and scalability. Only by resolving these engineering challenges can telomere-targeting nucleic acid therapeutics become a routine modality for treating cancer and aging-related diseases.

Insufficient Research and Future Perspectives

Despite the promising advancements discussed, several critical gaps remain in the current research landscape of telomere-targeting delivery. Firstly, regarding the dense chromatin environment of living organisms, high-resolution, real-time imaging tools that can quantifying the intra-nuclear kinetic behavior of nucleic acid payloads are still lacking. Consequently, it is challenging to capture the dynamic "binding-release" efficiency at chromosomal ends. Secondly, long-term biosafety data remains insufficient. Given that telomere modulation in regenerative medicine or oncology often requires chronic intervention, the potential risks of genomic instability or accidental cancer growth caused by long-term telomerase activation not yet fully understand. Thirdly, most delivery platforms prioritize the stage of entering the nucleus. However, effective treatment requires the drug to stay at the telomeres. Research on how to optimize these drugs degraded or exported inside the nucleus are insufficient. Understanding the kinetic law are essential to ensure the drug stays active long enough to work.

References

[1] Kulkarni, J.A., Witzigmann, D., Thomson, S.B., et al. (2021) 'The current landscape of nucleic acid therapeutics', Nature Nanotechnology, 16, pp. 630–643.

[2] Roberts, T.C., Langer, R. and Wood, M.J.A. (2020) 'Advances in oligonucleotide drug delivery', Nature Reviews Drug Discovery, 19, pp. 673–694.

[3] Bavelaar, B.M., Lee, B.Q., Williams, M.R., et al. (2021) 'Oligonucleotide-Functionalized Gold Nanoparticles for Synchronous Telomerase Inhibition, Radiosensitization, and Delivery of Theranostic Radionuclides', Molecular Pharmaceutics, 18(10), pp. 3782-3795.

[4] Springer, A.D. and Dowdy, S.F. (2018) 'GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics', Nucleic Acid Therapeutics, 28(3), pp. 109-118.

ISSN 2959-409X

[5] Uppada, S.B., Erickson, A.I., Wojdyla, L., et al. (2014) 'Elucidating the mechanism of action of T-oligo in inhibiting melanoma cell proliferation and inducing apoptosis', International Journal of Nanomedicine, 9, pp. 3437-3449.

[6] Nair, J.K., Willoughby, J.L., Chan, A., et al. (2014) 'Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing', Journal of the American Chemical Society, 136(49), pp. 16958-16961.

[7] Tenchov, R., Bird, R., Curtze, A.E., et al. (2021) 'Lipid Nanoparticles—From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement', ACS Nano, 15(11), pp. 16982–17015.

[8] Patel, S., Ashwanikumar, N., Sun, E., et al. (2017) 'Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA', Nano Letters, 17(9), pp. 5711–5718.

[9] Cheng, Q., Wei, T., Farbiak, L., et al. (2020) 'Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing', Nature Nanotechnology, 15, pp. 313–320.

[10] Busatto, S., Morad, G., Guo, P., et al. (2020) 'Polymer-based delivery of therapeutic nucleic acids: overcoming the barriers', Molecular Therapy, 28(8), pp. 1765–1782.

[11] Ghareghomi, S., Moosavian, S.A., Rahmati, M., et al. (2021) 'Co-delivery of hTERT siRNA and wortmannin by PLGA/chitosan nanoparticles for ovarian cancer therapy', Life Sciences, 270, p. 119129.

[12] Bulcha, J.T., Wang, Y., Ma, H., et al. (2021) 'Viral vector platforms within the gene therapy landscape', Signal Transduction and Targeted Therapy, 6, p. 53.

[13] Wang, H., Liu, Y., Li, Z., et al. (2015) 'Mannan-modified adenovirus encoding VEGFR-2 and TERT elicits potent antitumor immunity', Cancer Immunology, Immunotherapy, 64, pp. 935–945.

[14] Shirley, J.L., de Jong, Y.P., Terhorst, C., et al. (2020) 'Immune responses to viral gene therapy vectors', Molecular Therapy, 28(3), pp. 709–722.

[15] Poon, W., Zhang, Y.N., Ouyang, B., et al. (2019) 'Elimination pathways of nanoparticles', ACS Nano, 13(5), pp. 5785–5798.

[16] Hua, Y., Wu, M., Zhang, Y., et al. (2021) 'Poly(lactic-co-glycolic acid) microsphere production based on microfluidics for drug delivery', Drug Delivery, 28(1), pp. 1386-1398.

[17] Teo, S.L.Y., Birkenfeld, K., Cohen, J., et al. (2021) 'Unravelling cytosolic delivery of cell penetrating peptides with a quantitative endosomal escape assay', Nature Communications, 12, p. 3721.

[18] Beach, M.A., Zhang, X. and Zhang, Y. (2022) 'Quantifying the Endosomal Escape of pH-Responsive Nanoparticles Using the Split Luciferase Endosomal Escape Quantification Assay', ACS Applied Materials & Interfaces, 14(3), pp. 3653-3661.

[19] Ding, H. and Wu, F. (2012) 'Image Guided Biodistribution and Pharmacokinetic Studies of Theranostics', Theranostics, 2(11), pp. 1040-1053